TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04174118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belcesiran
Description: belcesiran will be administered subcutaneously (SC) at dose levels planned.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% NaCL) matching volume of belcesiran doses will be administered subcutaneously (SC).
Study: NCT01682187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Administered orally
Study: NCT00985751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189242A (formulation 1)
Description: Three doses will be administered intramuscularly, at Month 0, 2 and 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189242A (formulation 2)
Description: Three doses will be administered intramuscularly, at Month 0, 2 and 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 3)
Description: Three doses will be administered intramuscularly, at Month 0, 2 and 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 4)
Description: Three doses will be administered intramuscularly, at Month 0, 2 and 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A
Description: Three doses will be administered intramuscularly, at Month 0, 2 and 6
Study: NCT03681938

Intervention type: PROCEDURE
Intervention: Autograft
Description: Autograft
Study: NCT01816360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory aromatherapy
Description: Inhalation of essential oils.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory aromatherapy
Description: Inhalation of essential oils.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogatherapy
Description: Yogatherapy respiratory exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogatherapy
Description: Yogatherapy respiratory exercises.
Study: NCT05633251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variable (random) interval
Description: Using Variable (Random) Interval Reinforcement Schedules to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
Study: NCT01397812

Intervention type: DEVICE
Intervention: BreathScanner 1.0
Description: For the HeartsBreath test, breath is collected using BreathScanner 1.0 and sent to central laboratory for analysis for markers of transplant rejection.

Intervention type: DEVICE
Intervention: BreathLink
Description: The BreathLink point-of-care system detects and quantifies the breath VOC's determined to be biomarkers during the development of the Heartsbreath test.
Study: NCT03391531

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bilateral subcostal TAP block
Description: Echo-guided infiltration of a local anesthetic solution in the plane located between the transversus abdominis muscle and the rectus abdominis muscle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral subcostal TAP block
Description: Echo-guided infiltration of a local anesthetic solution in the plane located between the transversus abdominis muscle and the rectus abdominis muscle
Study: NCT03049527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education, Incentives and Feedback
Description: The study participants will receive additional educational activities, including low-literacy fact sheets on liquid intake guidelines, cards with instructions on how to self-monitor urine color and volume, and flyers and posters placed throughout the worksite. All consenting study participants will be offered incentives to start the work day hydrated and then to maintain or improve their hydration status over the work shift. Participants who do not meet hydration goals will receive additional coaching and feedback on ways to improve hydration.Feedback will also be provided to all groups about their productivity level to help participants recognize the connection between improved health and function.
Study: NCT03624829

Intervention type: OTHER
Intervention: Shared care
Description: The intervention is an adapted version of shared care with close collaboration by services and professional groups, mainly localized in three GP centers. At each GP center one clinical psychologist specialist from the community mental health center (CMHC) works two and a half day a week, and a psychiatrist from the CMHC work at each GP center 1-2 hours a week. The psychologist and the psychiatrist are available for the GPs for consultation and discussions, and they give assessments and brief treatments to patients as requested by the GPs. Other primary health and social care and other specialized mental health or substance addiction services are involved or consulted according to needs of the patients.
Study: NCT03636737

Intervention type: OTHER
Intervention: pathology associated
Description: list of pathology associated to Pyoderma gangrenosum
Study: NCT00515008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Intervention
Description: The tai chi intervention took place twice a week for 12 weeks, and each session lasted for 60 minutes. Classes were taught by a tai chi master with more than 20 years of teaching experience. In the first session, he explained the theory behind tai chi and its procedures and provided participants with printed materials on its principles and techniques. In subsequent sessions, participants practiced 10 forms from the classic Yang style of tai chi18 under his instruction. Each session included a warm-up and self-massage, followed by a review of principles, movements, breathing techniques, and relaxation in tai chi. Throughout the intervention period, participants were instructed to practice tai chi at home for at least 20 minutes each day. At the end of the 12-week intervention, participants were encouraged to maintain their tai chi practice, using an instructional DVD, up until the follow-up visit at 24 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Intervention
Description: Our wellness education and stretching program similarly included 60-minute sessions held twice a week for 12 weeks.19 At each session, a variety of health professionals provided a 40-minute didactic lesson on a topic relating to fibromyalgia, including the diagnostic criteria; coping strategies and problem-solving techniques; diet and nutrition; sleep disorders and fibromyalgia; pain management, therapies, and medications; physical and mental health; exercise; and wellness and lifestyle management.20 For the final 20 minutes of each class, participants practiced stretching exercises supervised by the research staff. Stretches involved the upper body, trunk, and lower body and were held for 15 to 20 seconds. Participants were instructed to practice stretching at home for 20 minutes a day.
Study: NCT01080989

Intervention type: OTHER
Group type: OTHER
Intervention: diagnosis, treatment and education
Description: Drug:~anti-intestinal parasitic drugs:~1. mebendazole 500mg one dose (For Hook worm infections, Ascariasis, Trichuriasis)~2. albendazole(400 mg bid \* 7days) or Ivermectin(200 mcg/kg/day \* 2 days) (For Strongyloidiasis).~Behavior:~1. Education capacity building (for local health personals): promote their ability of diagnosis and education to the community and patients for the associated diseases in this study.~2. Assist the trained local health personals to educate the patients and the community from the design of teaching materials and the contents.
Study: NCT01093573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone marrow aspiration
Description: Correlative study: Pretreatment bone marrow aspirates or blood \[(3 ml in EDTA tube (purple top)\] will be analyzed according to local institution guidelines to determine whether blasts contain wild type Flt3, ITD, or Flt 3 mutations.
Study: NCT03285711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: 200 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: 200 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib
Description: 30 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib
Description: 30 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib placebo
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib placebo
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib placebo
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib placebo
Description: Tablet administered orally once daily
Study: NCT03664323

Intervention type: BIOLOGICAL
Intervention: Evaluate the improvement in response from the end of anti-PD-1 monotherapy
Description: Evaluate the improvement in response from the end of anti-PD-1 monotherapy to the first evaluation after introduction of CT alone (Group 1) or combined with anti-PD-1 (Group 2).

Intervention type: BIOLOGICAL
Intervention: Evaluate the improvement in response from the end of anti-PD-1 monotherapy
Description: Evaluate the improvement in response from the end of anti-PD-1 monotherapy to the first evaluation after introduction of CT alone (Group 1) or combined with anti-PD-1 (Group 2).
Study: NCT02800811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FR104
Description: GMP FR104 is provided to the site in extractable volume vials containing FR104. Appropriate Dilutions in Ringer's lactate solution is made on site.
Study: NCT01093573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone marrow aspiration
Description: Correlative study: Pretreatment bone marrow aspirates or blood \[(3 ml in EDTA tube (purple top)\] will be analyzed according to local institution guidelines to determine whether blasts contain wild type Flt3, ITD, or Flt 3 mutations.
Study: NCT02800811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FR104
Description: GMP FR104 is provided to the site in extractable volume vials containing FR104. Appropriate Dilutions in Ringer's lactate solution is made on site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FR104
Description: GMP FR104 is provided to the site in extractable volume vials containing FR104. Appropriate Dilutions in Ringer's lactate solution is made on site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FR104
Description: GMP FR104 is provided to the site in extractable volume vials containing FR104. Appropriate Dilutions in Ringer's lactate solution is made on site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FR104
Description: GMP FR104 is provided to the site in extractable volume vials containing FR104. Appropriate Dilutions in Ringer's lactate solution is made on site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FR104
Description: GMP FR104 is provided to the site in extractable volume vials containing FR104. Appropriate Dilutions in Ringer's lactate solution is made on site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FR104
Description: GMP FR104 is provided to the site in extractable volume vials containing FR104. Appropriate Dilutions in Ringer's lactate solution is made on site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FR104
Description: GMP FR104 is provided to the site in extractable volume vials containing FR104. Appropriate Dilutions in Ringer's lactate solution is made on site.
Study: NCT05633251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variable (random) interval
Description: Using Variable (Random) Interval Reinforcement Schedules to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variable (non-random) interval
Description: Using Variable (Non-random) Interval Reinforcement Schedules to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variable (random) interval with table tents
Description: Using Variable (Random) Interval Reinforcement Schedules and Table Tents with Health-related Messages to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: No intervention
Study: NCT03395340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 1.5% cream
Description: Topical formulation of ruxolitinib, a Janus kinases (JAK) 1/2 inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle cream
Description: Matching vehicle cream applied as a thin film
Study: NCT05633251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: No intervention
Study: NCT02684240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: nitazoxanide 1000 mg orally twice daily with food for 14 days

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The control arm will receive WHO standard therapy for tuberculosis with isoniazid, rifampin, pyrazinamide, and ethambutol
Study: NCT01129791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Raw Milk
Description: Organic whole raw cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. for 8 days. After a 1-week wash-out period, pasteurized cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pasteurized Milk
Description: Organic whole pasteurized cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-dairy milk
Description: Unflavored soy milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or pasteurized cow's milk were consumed in the same fashion for another 8 days each.
Study: NCT03416582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Management Education and Nurse Coaching
Description: The registered nurse (RN) will teach good mouth care and management of sore mouth or throat (mucositis) symptoms to the patient for self-management at home. The RN will then call the patient twice every week to continue educating and coaching the patient about the mucositis self-management. The patient will receive the Symptom Management (SxM) Toolkit which is a written educational guide known as the Cancer Treatment Symptom Management Education Toolkit geared to help the patient manage their symptoms of sore mouth and throat at home in order to prevent dehydration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drinks Diary
Description: The patient will complete the Drinks Diary daily by recording the all oral fluid ingested and also record the number of times the bathroom is used.
Study: NCT02434315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Pro 4 sensor wears, 2 with reviews
Description: Subjects will wear the FreeStyle Libre Pro System for 14 days. 2 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Pro 6 sensor wears, 4 with reviews
Description: Subjects will wear the FreeStyle Libre Pro System for 14 days. 4 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FreeStyle Libre Pro 3 sensor wears
Description: Subjects will wear the FreeStyle Libre Pro System for 14 days. 3 periods of Sensor wear for time in range measurement over a period of approximately 8 months.
Study: NCT04072237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MarzAA (marzeptacog alfa [activated])
Description: Single intravenous dose and ascending doses of subcutaneous injection of MarzAA (Coagulation Faction VIIa Variant)
Study: NCT01102660

Intervention type: DRUG
Group type: OTHER
Intervention: PH-797804
Description: Tablet, 6 mg once daily for 2 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Tablet, 0 mg once daily for 2 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Tablet, 0 mg once daily for 2 weeks
Study: NCT02369406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra
Study: NCT02384499

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASC injection
Description: Allogenic-adipose-derived mesenchymal stem cells (ALLO-ASC) injection to the anal sphincter of patients with fecal incontinence

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% normal saline with fibrin glue injection to the anal sphincter of patients with fecal incontinence
Study: NCT02800811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FR104
Description: GMP FR104 is provided to the site in extractable volume vials containing FR104. Appropriate Dilutions in Ringer's lactate solution is made on site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FR104
Description: GMP FR104 is provided to the site in extractable volume vials containing FR104. Appropriate Dilutions in Ringer's lactate solution is made on site.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo injection contains the vehicle. For placebo dosing, vehicle is administered in accordance with the volume of study drug administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo injection contains the vehicle. For placebo dosing, vehicle is administered in accordance with the volume of study drug administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo injection contains the vehicle. For placebo dosing, vehicle is administered in accordance with the volume of study drug administered.
Study: NCT03328559

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ISET® - Isolation by Size of Tumor cells
Description: early stage bronchial cancer patient will have a blood collection
Study: NCT02942550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylnaltrexone bromide (Relistor®).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9mg/mL
Study: NCT05447130

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification
Description: phacoemulsification with corneal endothelial evaluation by specular microscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification
Description: phacoemulsification with corneal endothelial evaluation by specular microscopy
Study: NCT02629497

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Primrose oil
Description: T2DM patients and matched controls subjects will be given Primrose oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
Study: NCT02369406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Study: NCT02629497

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Primrose oil
Description: T2DM patients and matched controls subjects will be given Primrose oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: T2DM patients and matched controls subjects will be given Fish oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: T2DM patients and matched controls subjects will be given Fish oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
Study: NCT02369406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Study: NCT03643744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: 14 Celecoxib 200mg taken 1 in the morning and 1 in the evening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: 14 Celecoxib 200mg taken 1 in the morning and 1 in the evening.
Study: NCT03328559

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ISET® - Isolation by Size of Tumor cells
Description: advanced stage bronchial cancer patient will have a blood collection
Study: NCT00886132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 37.5 mg taken orally, daily every 28-day cycles
Study: NCT02022683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELVR (Endoscopic Lung Volume Reduction) with Zephyr Valves
Study: NCT00504166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alendronate sodium
Description: alendronate sodium 70 mg tablet once week for 24 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: placebo to match alendronate sodium one tablet once a week for 24 months
Study: NCT04379804

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral approach
Description: Following the ligation of upper pole vessels, the thyroid lobe was pulled anteromedially and the RLN was dissected within the carotid triangle at the level of inferior thyroid artery (ITA).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cranio-caudal approach
Description: Following the ligation of upper pole vessels, the upper pole was retracted antero-medially to expose crico-pharyngeal muscle. The RLN was identified at the point of entry both visually and with hand held stimulation probe